Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study

BackgroundNeoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates. The aim of this study was to compare 3-year follow-up data for patients with...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hai Zhang, Haiquan He, Qingyi Feng, Bomeng Wu, Ying Chen, Zhenyang Zhang, Linrong Zhou, Cui Li, Wanli Lin, Jiangbo Lin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-01-01
Edice:	Frontiers in Oncology
Témata:	esophageal squamous cell carcinoma immunotherapy neoadjuvant chemoradiotherapy pathological complete response recurrence-free survival
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1463936/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!